RxDoctor Payments Data

Pragnesh Patel, DPM

Foot & Ankle Surgery · Philadelphia, PANPI 1346604345

Payments from drug & device makers

$3,034in general payments, 2019–2025

Across 81 payments — averaging $37.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$695
  • Treace Medical Concepts, Inc.$501
  • Zimmer Biomet$428
  • Averitas Pharma Inc.$358
  • Stryker$280
  • Johnson & Johnson$112
  • plus $659 from 17 others

What the payments were for

  • Travel & lodging$1966%
  • Food & beverage$2,83894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,034 in reported general payments places this provider in the 55th percentile of 575 foot & ankle surgery providers in Pennsylvania.

See all foot & ankle surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,131
Medicare patients
456
Services billed
1,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$4,443
Ammonium Lactate125$2,197
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort35$2,035
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip87$1,383
Gabapentin105$1,379
Diclofenac Sodium21$848
Pregabalin12$827
Clindamycin Phosphate23$704
Mupirocin84$626
Doxycycline Hyclate39$606
Ciclopirox14$300
Cephalexin44$269
Terbinafine Hcl14$251
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim37$157
Triamcinolone Acetonide29$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$695$4,44313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 575 foot & ankle surgery providers in Pennsylvania.

Other foot & ankle surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →